Afatinib

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2590 publications

A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance.

A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: June 01, 2026

Establishment of pediatric neuroblastoma cell line and its resistance mechanism to lorlatinib

Establishment of pediatric neuroblastoma cell line and its resistance mechanism to lorlatinib

Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]
Published: May 18, 2026

Gender Differences in EGFR-TKI-Related Adverse Events: A Pharmacovigilance Study Based on the FAERS Database.

Gender Differences in EGFR-TKI-Related Adverse Events: A Pharmacovigilance Study Based on the FAERS Database.

Journal: Cancer control : journal of the Moffitt Cancer Center
Published: May 16, 2026

Long-term cardiotoxicity outcomes of trastuzumab and cardiac safety of novel HER2-targeted therapies.

Long-term cardiotoxicity outcomes of trastuzumab and cardiac safety of novel HER2-targeted therapies.

Journal: Expert opinion on drug safety
Published: May 04, 2026

Correction: Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study.

Correction: Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study.

Journal: Targeted oncology
Published: April 29, 2026

A Durable Response to Low-Dose Afatinib After Progression on Osimertinib in Advanced Epidermal Growth Factor Receptor (EGFR) L861Q-Mutated Lung Adenocarcinoma: A Case Report.

A Durable Response to Low-Dose Afatinib After Progression on Osimertinib in Advanced Epidermal Growth Factor Receptor (EGFR) L861Q-Mutated Lung Adenocarcinoma: A Case Report.

Journal: Cureus
Published: April 17, 2026

EZH2 Inhibition Remodels Cell States and Enhances EGFRi Sensitization in Bladder Cancer.

EZH2 Inhibition Remodels Cell States and Enhances EGFRi Sensitization in Bladder Cancer.

Journal: European urology oncology
Published: April 13, 2026

Management of periungual pyogenic granulomas due to EGFR inhibitors in real world.

Management of periungual pyogenic granulomas due to EGFR inhibitors in real world.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: April 10, 2026

Multi-omics analysis identified SPRR2D as a potential biomarker for tumor prognosis and immune microenvironment infiltration: a pan-cancer perspective.

Multi-omics analysis identified SPRR2D as a potential biomarker for tumor prognosis and immune microenvironment infiltration: a pan-cancer perspective.

Journal: Future science OA
Published: April 04, 2026

4-Anilinoquinazoline carbamate derivatization as a platform for prodrug design and localized drug delivery.

4-Anilinoquinazoline carbamate derivatization as a platform for prodrug design and localized drug delivery.

Journal: Bioorganic chemistry
Published: March 23, 2026

Severe IL-6-dominant immune-mediated inflammatory response complicated by probable arginine vasopressin deficiency following ivonescimab-based therapy in advanced EGFR-mutant lung squamous cell carcinoma: a case report.

Severe IL-6-dominant immune-mediated inflammatory response complicated by probable arginine vasopressin deficiency following ivonescimab-based therapy in advanced EGFR-mutant lung squamous cell carcinoma: a case report.

Journal: Frontiers in oncology
Published: March 23, 2026

LRRC46 regulates bovine granulosa cell functions via the COL8A1-mediated EGFR/PI3K/AKT signaling pathway.

LRRC46 regulates bovine granulosa cell functions via the COL8A1-mediated EGFR/PI3K/AKT signaling pathway.

Journal: Theriogenology
Published: March 19, 2026
Showing 1-12 of 2,590

Last Updated: 06/30/2026